🔬 Moderna's mFlusiva Gets Green Light as mRNA Flu Vaccine
Moderna's mFlusiva has been approved as the first mRNA-based influenza vaccine by a gastroenterology advisor. This approval pertains to the vaccine being developed by Moderna. The specifics mentioned relate to the vaccine's development timeline, though exact dates are not provided in the source. This marks a significant step in mRNA vaccine technology application for flu protection. Further clinical trials and widespread rollout are expected to follow this initial approval. 🔬